HiFiBiO Therapeutics, a clinical-stage biotherapeutics company, announced on Monday that it has raised $75 million in an oversubscribed Series D round funding led by new investor Mirae Asset Financial Group. The lead investor is a Korean global financial services group with $563 billion in assets under management.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
